Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07821762 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of Empasiprubart as Add-On Therapy to IVIg in Adult Participants With Guillain-Barré Syndrome

Study acronym: embridge
StatusNot Yet Recruiting
PhasePhase 2
Sponsorargenx
Started2026-12
View on ClinicalTrials.gov ↗
Argenx
56 trials monitored
See 2 trials at risk
The main purpose of this study is to learn whether empasiprubart, when given in addition to intravenous immunoglobulin (IVIg), helps adults with Guillain-Barré syndrome (GBS) recover and whether it is safe. About 63 participants will be assigned by chance to receive either empasiprubart or placebo by intravenous infusion; all participants will also receive IVIg. The study includes screening for up to 72 hours, study treatment through Day 12, and follow-up through Week 67 (15 months after the last dose of study treatment). Participation lasts up to 67 weeks.
Trial Details
NCT Number NCT07821762
Lead Sponsor argenx
Conditions Guillain-Barré Syndrome (GBS)
Enrollment 63 participants
Start Date 2026-12
Primary Completion 2028-01 (estimated)
Study Completion 2029-03 (estimated)
Updated on ClinicalTrials.gov 2026-09-25